Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE 60 versus OMNIPAQUE 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE 60 versus OMNIPAQUE 350.
DIATRIZOATE-60 vs OMNIPAQUE 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
1-2 mL/kg IV up to 150 mL for CT; 30-50 mL IV for DSA; max 350 mL per procedure.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent